Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Ottawa

$17,500.00

Identification of Phosphatase Inhibitors for Host-Directed Tuberculosis Therapy

FY 2019-20

Summary
"Tuberculosis (TB) is a top 10 cause of death worldwide. It is caused by the Mycobacterium tuberculosis (Mtb) bacteria, which infects immune cells known as macrophages and has developed many ways of resisting antibiotic treatments as well as our immune responses. Mtb can hijack our own cells' processes and use them for itself to ensure its survival as well as shutting down our antimicrobial defenses for protection. One new form of TB therapy is ""host-directed therapy"" (HDT), in which our own cells are targeted to try and restore these antimicrobial functions so that we can be more efficient at killing the bacteria ourselves. We have previously identified a host protein known as PPM1A which was shown to be essential for Mtb in order to block defense mechanisms and ensure its survival during infection. We also showed that when PPM1A is genetically deleted in cells, these defenses are restored, and the cell regains its Mtb killing abilities. A drug compound that can inhibit PPM1A does exist, but it is highly toxic. This project therefore aims to test new compounds designed to be PPM1A inhibitors and evaluate if they are able to enhance macrophages and allow them to regain their killing abilities. This will be done by assessing things like activity against PPM1A, cellular toxicity, and ability to increase bacterial killing both within cells and mouse systems. Any active compounds will be followed-up by studying potential mechanisms of action so that we can understand what it does within the cell, as well as looking into how it physically interacts with the PPM1A protein. Ideally, these compounds will provide a new way of fighting TB, contribute to better treatment outcomes for patients, and help curb the rise in antibiotic-resistant TB cases."
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
428946
Name
Liang Yi Chu
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Identification of Phosphatase Inhibitors for Host-Directed Tuberculosis Therapy
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Antibiotic Resistance; Drug Discovery; Drug Testing; Host-Directed Therapy; Immunology; Macrophage; Microbiology; Treatment; Tuberculosis
Abstract
"Tuberculosis (TB) is a top 10 cause of death worldwide. It is caused by the Mycobacterium tuberculosis (Mtb) bacteria, which infects immune cells known as macrophages and has developed many ways of resisting antibiotic treatments as well as our immune responses. Mtb can hijack our own cells' processes and use them for itself to ensure its survival as well as shutting down our antimicrobial defenses for protection. One new form of TB therapy is ""host-directed therapy"" (HDT), in which our own cells are targeted to try and restore these antimicrobial functions so that we can be more efficient at killing the bacteria ourselves. We have previously identified a host protein known as PPM1A which was shown to be essential for Mtb in order to block defense mechanisms and ensure its survival during infection. We also showed that when PPM1A is genetically deleted in cells, these defenses are restored, and the cell regains its Mtb killing abilities. A drug compound that can inhibit PPM1A does exist, but it is highly toxic. This project therefore aims to test new compounds designed to be PPM1A inhibitors and evaluate if they are able to enhance macrophages and allow them to regain their killing abilities. This will be done by assessing things like activity against PPM1A, cellular toxicity, and ability to increase bacterial killing both within cells and mouse systems. Any active compounds will be followed-up by studying potential mechanisms of action so that we can understand what it does within the cell, as well as looking into how it physically interacts with the PPM1A protein. Ideally, these compounds will provide a new way of fighting TB, contribute to better treatment outcomes for patients, and help curb the rise in antibiotic-resistant TB cases."
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Liang, Yi Chu
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~